Brief: Onxeo H1 Net Loss Eur 8.8 Million

Valerio Therapeutics SA

27/07/2018 17:18

July 27 (Reuters) - Onxeo SA  C4X.PA :
    * * CLINICAL DEVELOPMENT OF ONXEO'S LEAD PRODUCT CANDIDATE
ASIDNA
PROGRESSING TO PLAN
    * SAYS PRELIMINARY SAFETY AND ACTIVITY RESULTS OF DRIIV-1
STUDY
ARE EXPECTED IN Q4 2018
    * SAYS TWO COMBINATION CLINICAL TRIALS WITH ASIDNA™ PLANNED
FOR
EARLY 2019
    * NEW OPTIMIZED CANDIDATE FROM PLATON PROPRIETARY PLATFORM
READY
TO ENTER PRECLINICAL STAGE BY END 2018
    * SAYS CASH POSITION OF EUR 11M AT JUNE 30, 2018 ENABLES AN
EXPANDED CLINICAL DEVELOPMENT PLAN OF ASIDNA™ INTO 2020
    * SAYS NEW OPTIMIZED CANDIDATE FROM PLATON™ PROPRIETARY
PLATFORM
READY TO ENTER PRECLINICAL STAGE BY END 2018
    * H1 NET LOSS EUR 8.8 MILLION VERSUS LOSS OF EUR 11.6
MILLION YEAR
AGO
    * H1 OPERATING LOSS EUR 5.5 MILLION VERSUS LOSS OF EUR 11.3
MILLION YEAR AGO
    * H1 REVENUE EUR 2.1 MILLION VERSUS EUR 3.4 MILLION YEAR AGO
    * SAYS S PATENTED CHEMISTRY PLATFORM ENABLES COMPANY TO
GENERATE
ADDITIONAL INNOVATIVE DNA-TARGETING DRUG CANDIDATES.
    * SAYS SEVERAL COMPOUNDS ARE CURRENTLY IN SELECTION AND
OPTIMIZATION PHASE AND ONXEO EXPECTS TO INITIATE PRECLINICAL
EVALUATION OF A NEW DRUG CANDIDATE BY END OF 2018

Source text for Eikon:  ID:nBw941r5va 
Further company coverage:  C4X.PA 

 (Gdynia Newsroom)
 ((Gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))